Immunization with the<i>Chlamydia trachomatis</i>Mouse Pneumonitis Major Outer Membrane Protein Can Elicit a Protective Immune Response against a Genital Challenge

Pal, Sukumar; Theodor, Ida; Peterson, Ellena M.; Maza, Luis M. de la

doi:10.1128/iai.69.10.6240-6247.2001

Cited by 103 publications

(103 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MALS and RI detectors were directly connected to a size exclusion chromatography system to perform the analysis. nMOMP purifications obtained from adherent HeLa 229 cells infected with C. trachomatis Serovars D, E, F, or J were compared with C. muridarum nMOMP which has been reported to exist as a trimer in Zwittergent 3–14 detergent micelles 37, 39. The SEC UV chromatogram of C. muridarum nMOMP showed one major peak that accounted for approximately 95% of the area under curve.…”

Section: Resultsmentioning

confidence: 99%

Spectroscopic analysis of chlamydial major outer membrane protein in support of structure elucidation

et al. 2018

View full text Add to dashboard Cite

Chlamydial major outer membrane protein (MOMP) is the major protein constituent of the bacterial pathogen Chlamydia trachomatis. Chlamydia trachomatis Serovars D–K are the leading cause of genital tract infections which can lead to infertility or ectopic pregnancies. A vaccine against Chlamydia is highly desirable but currently not available. MOMP accounts for ~ 60% of the chlamydial protein mass and is considered to be one of the lead vaccine candidates against C. trachomatis. We report on the spectroscopic analysis of C. trachomatis native MOMP Serovars D, E, F, and J as well as C. muridarum MOMP by size exclusion chromatography multi angle light scattering (SEC MALS), circular dichroism (CD) and attenuated total reflectance Fourier transform infrared spectroscopy (ATR‐FTIR). MOMP was purified from the native bacterium grown in either adherent HeLa cells or in different suspension cell lines. Our results confirm that MOMP forms homo‐trimers in detergent micelles. The secondary structure composition of C. trachomatis MOMP was conserved across serovars, but different from composition of C. muridarum MOMP with a 13% (CD) to 18% (ATR‐FTIR) reduction in β‐sheet conformation for C. trachomatis MOMP. When Serovar E MOMP was isolated from suspension cell lines the α‐helix content increased by 7% (CD) to 13% (ATIR‐FTIR). Maintenance of a native‐like tertiary and quaternary structure in subunit vaccines is important for the generation of protective antibodies. This biophysical characterization of MOMP presented here serves, in the absence of functional assays, as a method for monitoring the structural integrity of MOMP.

show abstract

Section: Resultsmentioning

confidence: 99%

Spectroscopic analysis of chlamydial major outer membrane protein in support of structure elucidation

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The disappointing results of MOMP as a vaccine candidate may in part be due to the failure to obtain the native conformation of MOMP in these immunization protocols (Pal et al, 2001). Regardless, efforts are under way to identify other Chlamydia antigens as a subunit vaccine consisting of multiple antigens is more likely to be effective at inducing protective immunity.…”

Section: Immune-mediated Control Of Chlamydia Infection 15mentioning

confidence: 99%

Immune-mediated control of Chlamydia infection

Roan

Starnbach²

2007

Cell Microbiol

View full text Add to dashboard Cite

SummaryInfection with the bacterium Chlamydia trachomatis can lead to a variety of diseases, including ectopic pregnancy, infertility and blindness. Exposure of the host to C. trachomatis stimulates multiple innate and adaptive immune effectors that can contribute towards controlling bacterial replication. However, these effectors are often insufficient to resolve the infection and prevent re-infection, and the continued presence of C. trachomatis within the host may induce immune effectors to chronically produce inflammatory cytokines. This may eventually lead to the tissue pathologies associated with the infection. Reducing the incidence and sequelae of infection will ultimately require the development of a C. trachomatis vaccine that can stimulate sterilizing immunity while avoiding immune-mediated pathology.

show abstract

“…The use of the major outer membrane protein (MOMP) as a vaccine candidate has been extensively studied, with varying success. [72][73][74][75][76][77][78][79] The use of this antigen has resulted from the fact that it constitutes approximately 60% of the outer membrane protein mass of the chlamydial EB. 47 However, MOMP contains four variable domains that are surface exposed and are antigenically variable between serovars.…”

Section: Treatment or Prevention?mentioning

confidence: 99%

REVIEW ARTICLE: Chlamydia trachomatis, a Hidden Epidemic: Effects on Female Reproduction and Options for Treatment

Carey

Beagley

2010

American J Rep Immunol

View full text Add to dashboard Cite

Citation Carey AJ, Beagley KW. Chlamydia trachomatis, a hidden epidemic: effects on the female reproduction and options for treatment. Am J Reprod Immunol 2010The number of genital tract Chlamydia trachomatis infections is steadily increasing worldwide, with approximately 50–70% of infections asymptomatic. There is currently no uniform screening practice, current antibiotic treatment has failed to prevent the increased incidence, and there is no vaccine available. We examined studies on the epidemiology of C. trachomatis infections, the effects infections have on the female reproductive tract and subsequent reproductive health and what measures are being taken to reduce these problems. Undetected or multiple infections in women can lead to the development of severe reproductive sequelae, including pelvic inflammatory disease and tubal infertility. There are two possible paradigms of chlamydial pathogenesis, the cellular and immunological paradigms. While many vaccine candidates are being extensively tested in animal models, they are still years from clinical trials. With no vaccine available and antibiotic treatment unable to halt the increased incidence, infection rates will continue to increase and cause a significant burden on health care systems.

show abstract

Immunization with theChlamydia trachomatisMouse Pneumonitis Major Outer Membrane Protein Can Elicit a Protective Immune Response against a Genital Challenge

Cited by 103 publications

References 57 publications

Spectroscopic analysis of chlamydial major outer membrane protein in support of structure elucidation

Spectroscopic analysis of chlamydial major outer membrane protein in support of structure elucidation

Immune-mediated control of Chlamydia infection

REVIEW ARTICLE: Chlamydia trachomatis, a Hidden Epidemic: Effects on Female Reproduction and Options for Treatment

Contact Info

Product

Resources

About